Quarterly Results of Operation (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

The following is a summary of the unaudited quarterly results of operations:

	2013 (in thousands except per share data)
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013			Total
Revenues	$	42		$	36		$	36		$	36		$	150
Costs and expenses	(4,604		)	(4,770		)	(4,495		)	(3,448		)	(17,317		)
Interest & other
Income (expense)	176			349			85			165			775
Other than temporary impairment loss on marketable securities	—			—			(800		)	—			(800		)
Sales of tax NOL	686			—			—			—			686
Redeemable warrants
valuation adjustment	89			102			38			52			281
Net loss	$	(3,611	)	$	(4,283	)	$	(5,136	)	$	(3,195	)	$	(16,225	)
Basic and diluted loss per share	$	(0.02	)	$	(0.03	)	$	(0.03	)	$	(0.02	)	$	(0.10	)

	2012 (in thousands except per share data)
	March 31, 2012			June 30, 2012			September 30, 2012			December 31, 2012			Total
Revenues	$	72		$	49		$	39		$	53		$	213
Costs and expenses	(3,819		)	(3,682		)	(5,004		)	(8,048		)	(20,553		)
Interest & other
Income (expense)	262			246			346			719			1,573
Sales of tax NOL	1,328			—			—			—			1,328
Redeemable warrants
valuation adjustment	(151		)	387			(1,968		)	1,817			85
Net loss	$	(2,308	)	$	(3,000	)	$	(6,587	)	$	(5,459	)	$	(17,354	)
Basic and diluted loss per share	$	(0.02	)	$	(0.02	)	$	(0.05	)	$	(0.03	)	$	(0.12	)

Schedule of Valuation and Qualifying Accounts

Hemispherx Biopharma, Inc.

Valuation and Qualifying Accounts Schedule

(dollars in thousands)

Description	Balance at beginning of period		Charge to expense		Write- offs			Balance at end of period
Year Ended December 31, 2011 Reserve for inventory	$	249	$	192	$	(249	)	$	192
Year Ended December 31, 2012 Reserve for inventory	$	192	$	1,023	$	—		$	1,215
Year Ended December 31, 2013 Reserve for inventory	$	1,215	$	458	$	(1,673	)	$	—